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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S292of both cytokines is effective early in the process of cartilage damage. In
this study it is investigated whether a single intra-articular injection of
IL-4 plus IL-10 immediately after a joint bleed limits cartilage damage in
an in vivo haemophilia mouse model.
Methods: Factor VIII knockout mice were punctured once with a needle
below the patella to induce a joint bleed. Subsequently IL-4 plus IL-10
(n¼24) or vehicle (n¼24) was injected intra-articularly once. After 35
days, the knee joints were examined for cartilage damage by macro-
scopic and microscopic evaluation using the OARSI histopathology
score speciﬁc for mice for cartilage degeneration and the Valentino
score for synovial inﬂammation. The left knee joint in both groups
served as an unaffected control.
Results: Induction of a joint bleed led to a signiﬁcant increase in
macroscopic remains of a joint bleed and to an increase in joint
diameter in both groups compared to the unaffected joints (all p<0.05
compared to control). Although not statistically signiﬁcant, the IL-4
plus IL-10 injected joints tended to present less remains of a joint
bleed compared to the vehicle injected joints (46% versus 58%;
p¼0.386). Moreover, the diameter of the joints injected with IL-4 plus
IL-10 tended to be smaller than that of the vehicle injected joints
(2.630.16mm vs 2.910.29mm; p¼0.174). After a joint bleed, the
OARSI score as well as the Valentino score increased compared to the
unaffected joints. Intra-articular injection of IL-4 and IL-10 amelio-
rated cartilage degeneration caused by the joint bleed (mean change
in OARSI score in experimental joint compared to control joint for
vehicle injection 0.91.2 (p¼0.010) and for IL-4 plus IL-10 injection
0.51.8 (p¼0.216)). No effect on inﬂammationwas observed at 35 days
after the joint bleed for IL-4 plus IL-10 compared to vehicle (mean
Valentino score after IL-4 plus IL-10 injection 3.61.8 and for vehicle
injection 2.92.0 (p¼0.220)).
Conclusion: A single intra-articular injection of IL-4 plus IL-10 directly
after a single joint bleed limits cartilage degeneration, but not synovial
inﬂammation. Improved bioavailability of both cytokines might
improve the protective ability of both cytokines in development of
cartilage degeneration, and probably also inﬂammation.
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Purpose: Intra-articular injections of hyaluronic acid (IA-HA) and oral
non-steroidal anti-inﬂammatory drugs (NSAIDs) are both recom-
mended by OARSI for the management of knee OA. However, their
molecular effects on the pathophysiology of knee OA remain unclear. A
C-terminal telopeptides of type II collagen (CTX-II) is biomarker
discovered as a marker of type II collagen degradation. Recently, CTX-II
has found to originate primarily from the interface between sub-
chondral bone and articular cartilage which is a site of potential
remodeling in OA. The regulation of CTX-II release is more reﬂective of
bone rather than cartilage metabolism. The aim of this study, the sub-
analysis of the multicenter RCT [the result of the primary endpoint
(OARSI 2012)] was to compare the changes of CTX-II in response to IA-
HA to those in response to NSAID treatment for knee OA.
Methods: A total of 200 patients with knee OA (K/L 1 to 3) were
registered from 20 hospitals and randomized to IA-HA (High molecular
weight 2,700 kDa HA) or NSAID (loxoprofen sodium). For patients
treated with NSAID, they used NSAID 3 tablets (180 mg)/day for 5
weeks. For patients treated with IA-HA, IA-HAwas conducted 5 times atoneweek intervals. The fasted second void urine samples collected from
all patients were stored at -80Co until analysis. uCTX-II levels were
corrected for urine creatinine concentration. The CTX-II data were
analyzed by the per protocol set (PPS).
Results: Half (100) of the patients were randomly allocated into the
NSAID group, and the other half allocated into the IA-HA group. After
the 5 week treatment period, 68 of 100 of the patients in the IA-HA
group and 58 of 100 of those in the NSAID group were eligible for CTX-II
analysis. At baseline, no signiﬁcant differences of baseline characteris-
tics were observed between IA-HA and NSAID groups. The Japanese
Knee Osteoarthritis Measure (JKOM) score of the patients in both the IA-
HA (-37.4%) and NSAID (-35.3%) groups were signiﬁcantly reduced
following treatment (p<0.001). The difference in the percent changes of
the JKOM score between the two intervention arms was -2.1% (90%CI;
-10.9 to 6.2%), demonstrating the non-inferiority of IA-HA to the NSAID
for the reduction in the clinical symptoms. uCTX-II levels were signiﬁ-
cantly reduced by the NSAID treatment. In contrast, uCTX-II levels were
signiﬁcantly increased by the IA-HA treatment. The percent changes of
uCTX-II by IA-HA treatment (11.6%) were signiﬁcantly different than
those of that by NSAID treatment (-9.0%) (p<0.0001). When the
patients were analyzed based on the radiographic severity of knee OA,
the differences of uCTX-II responses between the NSAID and IA-HA
were again observed.
Conclusions: We observed in this RCT that IA-HA treatment increased
uCTX-II levels, while oral NSAID reduced uCTX-II levels, while both
treatments improved symptoms of pts. with knee OA. The differences in
biomarker response suggest different modes of action, each with
a beneﬁcial effect on symptom: one being stimulatory of cartilage/bone
interface extracellular matrix type II collagen turnover (IA-HA) and the
other reducing such turnover.
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Purpose: Tumor necrosis factor alpha (TNFa) is believed to be a key
mediator of inﬂammatory events associated with herniated interver-
tebral disc (IVD). Local delivery of TNF antagonists via epidural injec-
tions to treat pain or dysfunction associated with herniated IVD has
been studied in the clinic with some success. We hypothesize that
sustained release of injectable depots containing cytokine antagonists
can be a safer, cost-effective treatment for relieving pain associated
with IVD herniation. We have designed novel drug conjugates
comprised of elastin-like polypeptides (ELP) and a small anti-inﬂam-
matory compound, curcumin, which has an excellent safety proﬁle in
clinical trials. ELPs are biocompatible, biodegradable polymers that are
soluble below a transition temperature (Tt,) and form micron-sized
depots above Tt. Here, we report on the pharmacokinetics and clearance
rates of injectable, ELP-curcumin conjugate ‘depots’ delivered to the
perineural space in mice.
Methods: A novel derivative of curcumin, monofunctional curcumin
carbamate (MCC, Fig 1), was chemically coupled to glutamate-con-
taining ELPs (Fig 2). Drug-carrier ratio, conjugate purity, Tt, and
hydrodynamic radius (Rh) were quantiﬁed with UV-Vis, RP-HPLC, and
dynamic light scattering. In vitro bioactivity of conjugates against TNFa-
induced proliferation was quantiﬁed with L929 cells as previously
described. For in vivo studies, the right sciatic nerve of C57BL/6 female
mice (n¼3 per group, 12 weeks old) was surgically exposed, and cur-
cumin or ELP-MCC (25ml, 150nmol) was delivered to the perineural
space. Blood was collected at times from 0.5 to 168 hours and tissues
were harvested at varying sacriﬁce times from 2 to 168 hours. Plasma
and solubilized tissue was analyzed for curcumin presence via
ﬂuorescence.
Results: ELP-MCC conjugates were synthesized and characterized to
have mean drug-carrier ratios of 5.7 to 1 (MW¼37.8kDa), >90% purity,
